Nosocomial Infection Treatment Market By Infection (Ventilator Associated Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Gastrointestinal Infection, MRSA), By Treatment (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

The World Health Organization defines nosocomial infection as "an infection acquired in hospital by a patient who was admitted for a reason other than that infection." an infection occurring in a patient in a hospital or other healthcare facility in whom the infection was not present or incubating at the time of admission. This includes infections acquired in the hospital but appearing after discharge, as well as occupational infections among the staff of the facility.

The infection is caused by bacteria, viruses, fungi, and parasites. Because of an extended stay in the hospital, the use of indwelling catheters, some failure on the part of the health care provider, or an antibiotic overdose, all hospital patients are susceptible to infection, particularly pediatric and geriatric patients and immune-compromised patients. The global nosocomial infection treatment market is anticipated to progress during the forecast period due to the rising prevalence of nosocomial infections, an increase in the number of surgical procedures, and an escalating focus on disinfection and sterilization technology.

The report titled "Global Nosocomial Infection Treatment Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2024" offers strategic insights into the overall nosocomial infection treatment market, along with the market size and estimates for the duration of 2014 to 2024. The study provides an in-depth analysis of multiple market segments based on product type and geography.

The infection types studied for analyzing the overall nosocomial infection treatment market are majorly segmented into ventilator-associated pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA, and others. The treatment types considered for analyzing the market are antibacterial, antifungal, antiviral, and others.

Geographically, the global nosocomial infection treatment market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
  • Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2014–2024. Market growth rates for the forecast period 2016–2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global nosocomial infection treatment market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global nosocomial infection treatment market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global nosocomial infection treatment market. In-depth competitive environment analysis and historic market size data are also provided in the report.

Based on the type of infection, the global nosocomial infection treatment market is segmented as follows:

  • Ventilator-Associated Pneumonia
  • Infection of the Urinary Tract
  • bloodstream infection
  • Surgical site infection
  • Gastrointestinal Infection
  • MRSA
  • Others (ENT infections, skin infections, and bone infections)

Pneumonia and surgical site infections are the most common hospital-acquired infections, occupying the largest market share. Nosocomial pneumonia is observed in several varied groups. The patients on ventilators in the ICU are more susceptible to infection; the rate of infection caused by pneumonia is 3% per day and is associated with a high fatality rate. Surgical site infection is the next big concern, with the incidence rate varying from 0.5% to 15%, depending on the type of operation and patient status. Bloodstream infection accounts for almost 15% to 20% of nosocomial infections, affecting almost 1% of all hospitalized patients.

It is associated with an increased mortality rate and an extended stay in an intensive care unit and hospital; therefore, surveillance and prevention of BSI are high priorities. Urinary tract infection occurs due to the use of a bladder catheter and is associated with less morbidity compared to other nosocomial infections. MRSA is the second most common cause of HAIs reported to the NHSN. The CDC also estimates that 49% to 65% of hospital-acquired S. aureus infections reported to the NHSN are caused by methicillin-resistant strains.

Based on the type of treatment, the global nosocomial infection treatment market is segmented as follows:

  • Antibacterial Treatment
  • Antiviral Treatment
  • Antifungal Treatment
  • Others

Because of the risk of emergence of emergency situations, infection severity in neutropenia, and the large presence of immunocompromised and elderly patients, antibiotic therapy is empirical in the intensive care unit. The selection of antibiotic therapy depends upon the most common bacterial species causing infection, the pattern of antibiotic resistance in a particular hospital, the clinical status of the patient, and previous therapy.

It covers both gram-positive and gram-negative bacteria. Initial antibiotic therapy includes ceftazidime plus vancomycin; if vancomycin is not used, monotherapy with ceftazidime, imipenem, cefepime, or meropenem is given. Multiple antibiotics are used when the organism develops a resistant mutant, the patient is immunocompromised, higher serum activity is required, or the blood culture consistently shows positive bacteria even after a single therapy. The conventionally long-used initial regimen of combination therapy recommended includes antipseudomonal penicillin plus aminoglycoside or an antipseudomonal cephalosporin (ceftazidime) plus an aminoglycoside. Antifungal drugs are used to treat fungal infections.

These include amphotericin B, nystatin, ketoconazole, itraconazole, and fluconazole. Antiviral drugs used are acyclovir, ganciclovir, foscarnet, and amantadine, which inhibit the growth or multiplication of the virus. Empiric antibiotics, antivirals, and antifungals are used to treat infection and avoid any further complications, including organ damage.

Geographically, the global nosocomial infection treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

North America currently dominates the regional global nosocomial infection market, followed by Europe. The key drivers for the North American market are the rising prevalence of nosocomial infections, multi-drug-resistant microbes, and rising demand for advanced therapeutics.

The U.S. is the major market in North America due to incessant technological advancements in surgical procedures, sterilization equipment, and state-of-the-art healthcare facilities. Europe is the second largest market, owing to an increase in the geriatric population, which is susceptible to nosocomial infection, government initiatives to improve healthcare facilities, and advances in antimicrobial therapeutics.

Asia Pacific is the fastest growing market due to factors such as increasing investment in healthcare facilities, a rise in per capita income fueled by economic development, huge government investments in the development of healthcare infrastructure, and rising public awareness coupled with a high prevalence of nosocomial infection.

Frequently Asked Questions:

The market for Nosocomial Infection Treatment Market is expected to reach US$ 36,746 Mn By 2024.

The Nosocomial Infection Treatment Market is expected to see significant CAGR growth over the coming years, at 2.5%.

The report is forecasted from 2016-2024.

The base year of this report is 2015.

Becton, Dickinson and Company, Kimberly-Clark Corp., Sterigenics International, Inc., Sakura Seiki are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Feb 2017
Category:  Pharmaceuticals
Report ID:   58358
Report Format:   PDF
Pages:   120
Rating:    4.7 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support